GlassScriptPhysician profile
David R Bryson
NPI 1346248077
$40,785.22
in general payments reported to CMS, 2019-2025
90 companies · $6,549 in 2025
The $6,549 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,792 · 2020: $4,717 · 2021: $5,313 · 2022: $5,914 · 2023: $6,378 · 2024: $7,122 · 2025: $6,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Long Term Medical Supply Or Device Loan: $2,250 · Education: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,081.42 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Education | $717.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,847.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,970.63 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Exelixis INC. | $1,873.85 | 2019-2025 | Cabometyx |
| Puma Biotechnology, INC. | $1,757.94 | 2019-2025 | |
| Pfizer INC. | $1,621.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,607.76 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $1,486.94 | 2019-2025 | Polivy, Phesgo, Venclexta |
| Janssen Biotech, INC. | $1,449.61 | 2019-2025 | Erleada, Darzalex, Carvykti |
| Celgene Corporation | $1,286.16 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $1,262.18 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Amgen INC. | $1,247.26 | 2019-2023 | Xgeva, Lumakras, Vectibix |
| Genzyme Corporation | $1,047.94 | 2019-2025 | |
| Sobi, INC | $898.63 | 2022-2025 | |
| Seagen INC. | $854.09 | 2020-2023 | Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $835.01 | 2019-2025 | Opdivo |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $808.26 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $768.55 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Eisai INC. | $684.62 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $561.55 | 2019-2025 | |
| Lilly USA, LLC | $554.70 | 2019-2025 | Verzenio, Jaypirca |
| Incyte Corporation | $534.23 | 2019-2025 | Monjuvi, Jakafi |
| Aveo Pharmaceuticals, INC. | $531.45 | 2021-2025 | Fotivda |
| Abbvie INC. | $507.58 | 2019-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $429.15 | 2019-2025 | Ultomiris |
| Astellas Pharma US INC | $387.09 | 2019-2025 | Xospata, Vyloy, Padcev |
| Kite Pharma, INC. | $347.63 | 2020-2023 | Yescarta |
| Stemline Therapeutics INC. | $329.90 | 2019-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $303.88 | 2021-2025 | Libtayo, Lynozyfic |
| Array Biopharma INC | $296.30 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $288.65 | 2021-2025 | Onivyde, Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $244.20 | 2020-2025 | Iclusig, Ninlaro, Fruzaqla |
| Dova Pharmaceuticals | $231.70 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $219.77 | 2021-2023 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $216.19 | 2019-2022 | |
| Emd Serono, INC. | $191.47 | 2021-2025 | Bavencio |
| Deciphera Pharmaceuticals INC. | $187.64 | 2024-2025 | Qinlock, Romvimza |
| Kyowa Kirin, INC. | $180.89 | 2019-2022 | |
| Pharmaessentia USA Corporation | $163.02 | 2022-2025 | Besremi |
| Mirati Therapeutics, INC. | $151.91 | 2023-2024 | Krazati |
| Beigene USA, INC. | $148.60 | 2021-2025 | Brukinsa |
| Caris Mpi, INC. | $131.47 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $129.37 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $117.46 | 2022-2025 | |
| Organon LLC | $112.02 | 2024-2025 | |
| Medtronic, INC. | $105.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.50 | 2023-2025 | Gilotrif |
| Amneal Pharmaceuticals LLC | $98.07 | 2023-2025 | Neulasta, Avastin, Neupogen |
| Tersera Therapeutics LLC | $93.28 | 2019-2025 | Xermelo |
| Adc Therapeutics America, INC. | $91.45 | 2024-2025 | |
| Immunogen, INC. | $89.38 | 2023-2024 | Elahere, Elahere |
| Taiho Oncology, INC. | $88.86 | 2019-2023 | |
| Morphosys, US INC. | $78.20 | 2021-2023 | Monjuvi |
| Novocure INC. | $76.43 | 2024-2025 | Optune Lua (Novottf-200t) |
| Agios Pharmaceuticals, INC. | $68.55 | 2024-2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $68.06 | 2023-2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $63.19 | 2019-2025 | |
| Springworks Therapeutics, INC. | $62.77 | 2024-2025 | Ogsiveo |
| Secura Bio, INC. | $62.63 | 2021 | |
| Myriad Genetic Laboratories, INC. | $60.49 | 2022 | |
| Menarini Silicon Biosystems, INC. | $48.43 | 2025 | |
| Sumitomo Pharma America, INC. | $45.88 | 2024-2025 | Orgovyx |
| Octapharma USA, INC. | $44.80 | 2025 | Octagam Immune Globulin (Human) |
| Beone Medicines USA, INC. | $39.59 | 2025 | Brukinsa, Tevimbra |
| Recordati_rare_diseases_inc. | $38.60 | 2023 | Sylvant |
| G1 Therapeutics, INC. | $38.15 | 2022-2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $36.60 | 2022-2023 | Provenge |
| Sanofi-Aventis U.S. LLC | $33.21 | 2020-2021 | |
| Genmab U.S., INC. | $31.23 | 2023 | Epkinly |
| Fresenius Kabi USA, LLC | $30.26 | 2024 | Stimufend |
| Janssen Pharmaceuticals, INC | $25.67 | 2019-2022 | |
| Acceleron Pharma, INC. | $23.81 | 2020 | |
| Rigel Pharmaceuticals, INC. | $23.10 | 2022 | |
| Myovant Sciences INC. | $22.40 | 2022 | |
| Tempus Ai, INC | $21.38 | 2025 | Xt Cdx |
| Apellis Pharmaceuticals, INC. | $21.12 | 2023 | |
| Btg International INC. | $20.62 | 2021 | |
| Syndax Pharmaceuticals, INC. | $20.38 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $19.00 | 2019 | |
| Sirtex Medical INC | $17.39 | 2019 | |
| Cti Biopharma Corp. | $17.28 | 2023 | Vonjo |
| Tactile Systems Technology INC | $17.28 | 2024 | Flexitouch Plus, Entre Plus |
| Fennec Pharmaceuticals, INC. | $17.03 | 2025 | Fyarro |
| Verity Pharmaceuticals INC. | $16.50 | 2024 | Trelstar |
| Cumberland Pharmaceuticals, INC. | $16.41 | 2023 | Sancuso |
| Nuvation Bio INC. | $16.40 | 2025 | Ibtrozi |
| Blueprint Medicines Corporation | $14.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.05 | 2024 | Truxima |
| Foundation Medicine, INC. | $12.89 | 2019 | |
| Eusa Pharma (US) LLC | $11.90 | 2022 | |
| Mayne Pharma Commercial LLC | $11.60 | 2021 |
Drugs and devices associated with these payments
Kisqali $2,339Enhertu $1,327Calquence $1,187Cabometyx $839Keytruda $836Lynparza $766Polivy $572Imfinzi $487Doptelet $455Tagrisso $443Lenvima $423Fotivda $406Pluvicto $346Ibrance $336Tukysa $328Orserdu $313Reblozyl $302Scemblix $265Lutathera $259Injectafer $257Vonjo $252Erleada $249Verzenio $249Trodelvy $242Venclexta $240Phesgo $222Darzalex $218Saphnelo $212Carvykti $200Elahere $196Libtayo $192Zejula $192Adcetris $191Mektovi $189Braftovi $189Xtandi $188Qinlock $188Ojjaara $182Sarclisa $181Lorbrena $180Imbruvica $164Inlyta $163Stivarga $162Vitrakvi $162Onivyde $160Tecentriq $155Krazati $152Elrexfio $144Xalkori $141Nubeqa $141Fabhalta $140Monjuvi $140Rybrevant $134Ultomiris $133Mi Cancer Seek $131Lunsumio $128Xpovio $126Pomalyst $124Tecvayli $122Besremi $122Jemperli $118Udenyca $114Opdualag $114Talzenna $108Brukinsa $108Iclusig $105Talvey $104Jaypirca $103Ontruzant $93.35Xofigo $92.73Xospata $92.05Cablivi $91.65Enjaymo $91.65Welireg $87.59Bosulif $86.53Neulasta $83.23Avastin $83.23Neupogen $83.23Xgeva $82.08Promacta $78.06Optune Lua (Novottf-200t) $76.43Jakafi $73.28Tasigna $73.22Lumakras $73.19Piqray $72.15Opdivo $71.95Tibsovo $69.10Jevtana $68.86Pyrukynd $68.55Monoferric $68.06Paxlovid $63.66Ogsiveo $62.77Itovebi $61.75Datroway $61.39Epkinly $60.34Bavencio $53.69Blenrep $52.99Vectibix $52.71Nplate $52.71Cellsearch $48.43
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bryson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.